// App-Quantinova.ai

1470 : Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: efficacy results from the 1st line non-small cell lung cancer cohort of TACTI-002 (Phase II)

Researchers

Presenter

  • Wade Iams

Principal Investigators

  • Margarita Majem

  • Bernard Doger

  • Tim Clay

  • Enric Carcereny

  • Igor Bondarenko

  • Julio Peguero

  • Manuel Cobo-Dols

  • Martin Forster

  • Grygorii Ursol

  • Ewa Kalinka

  • Gema Garcia Ledo

  • Laia Vila Martinez

  • Matthew Krebs

  • Begona Campos Balea

  • Joanna Kefas

  • Christian Mueller

  • Chrystelle Brignone

  • Frederic Triebel

Medical Centers

  • City Clinical Hospital of Dnipro, Dnipro, Ukraine

  • University of Manchester and Christie NHS, Manchester, UK

  • Vanderbilt-Ingram Cancer Center, Nashville, TN

  • Immutep S.A.S., Chatenay-Malabry, France

  • Instytut Centrum Zdrowia Matki Polki, Lodz, Poland

  • Catalan Institute of Oncology, Badalona, Spain

  • St. Luke’s Hospital, Kropyvnytskyi, Ukraine

  • Parc Taulí Sabadell Hospital Univ., Barcelona, Spain

  • Hospital Regional Universitario de Malaga, Malaga, Spain

  • Hospital Santa Creu i Sant Pau, Barcelona, Spain

  • St John of God Hospital, Perth, Australia

  • Hospital Lucus Augusti, Lugo, Spain

  • Hospital Universitario Sanchinarro, Madrid, Spain

  • Oncology Consultants PA, Houston, TX

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • Univ. College London Hospitals NHS Trust, London, UK

  • University College London, London, UK

  • Fundacion Jimenez Diaz, Madrid, Spain

  • Immutep, Berlin, Germany

Locations

  • Ukraine

  • Spain

  • United Kingdom

  • United States

  • France

  • Germany

  • Australia

  • Poland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Programmed death-ligand 1

  • Interferon-gamma

Drug/Treatment

  • EDP 202

  • Pembrolizumab

  • IFN-lambda

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

  • Cohort

Phase

  • II

Study Id's

  • N/A

Sponsors

  • Immutep

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved